Suven Life Sciences granted patents for neurodegenerative drug

Tags: Companies
Pharmaceutical firm Suven Life Sciences has been granted three product patents -- one each by South Korea, China and Canada -- for drug used in the treatment of neurodegenerative diseases.

Neurodegenerative diseases include Alzheimer's disease, Schizophrenia and Parkinson's disease.

In a BSE filing the company said it has been granted "one product patent from South Korea, one product patent from China and one product patent from Canada corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".

These patents are valid through 2029, 2029 and 2031, respectively, the company said in a BSE filing.

Suven Life Sciences CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medial need with huge market potential globally."

With these new patents, Suven has a total of 14 granted patents from South Korea, 14 from China and 16 from Canada, respectively.

EDITORIAL OF THE DAY

  • E-wallet companies must make their revenue models sustainable

    At a time when e-wallets have come to be accepted as the new normal, HDFC chairman Aditya Puri’s contention that digital payment companies have no f

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Sandeep Bamzai

Disequilibrium: The Phantom of a Bloody Opera

As long as the walk between subjectivity and objectivity is ...

Sachin Shridhar

Strip numbers, see truth

Indian Parliament has over has over 34 per cent of ...

Kuruvilla Pandikattu

The eternal question of science & religion

Well-known physicist Stephen Barr, author of Modern Physics and ...